CellCept®(mycophenolate mofetil) – Expanded indication
June 6, 2022 - The FDA approved Genentech’s CellCept (mycophenolate mofetil), for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.
Top